Title
Category
Credits
Event date
Cost
  • 0.75 ANCC - Nurses
  • 0.75 Attendance - General Attendance
  • 0.75 CCMC - General - Case Managers
  • 0.75 ASWB - Social Workers
$0.00
Post-acute discharge planning that is adequate and specific to the patient’s care needs is essential to ensure continuity of care, reduce the rate of unplanned re-admissions and complications and improve the patient’s quality of life; appropriate planning also reduces inaccuracies and oversights during transitions of care. This activity aims to increase competency surrounding the post-acute discharge planning process. It will discuss the various levels of care and types of services available for post-acute discharge planning and examine the eligibility requirements specific to each setting, including how payer criteria can impact planning.
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
Bladder cancer (BC) is the tenth most common cancer worldwide, and its associated five-year survival rate declines rapidly (from 96% to 6%) as it progresses from in situ through local invasion, regional spread and finally to distal spread. Thus, early detection and timely therapeutic interventions are crucial to improve outcomes and reduce the burden of disease. Outcomes have been further improved by the integration of recently approved therapies for BC, the utilization of biomarkers to guide treatment plans and the opportunity for eligible patients with BC to enroll in clinical trials. For all treatment plans, effective communication among the health care team is crucial for providing comprehensive care for this condition. This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity discusses the current prevalence trends for CRC, new insight into risk factors, recommended screening approaches and modalities, treatment updates focused on tumor-specific molecular targets, and recent and emerging findings in CRC research and clinical trials.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of leukodystrophies, including current clinical trials. It will also share insights and perspectives from individuals and their family/caregiver(s) and provide strategies to support their well-being.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of Pompe disease and other LSDs, including current clinical trials. It will also share insights and perspectives from and provide strategies to support the well-being of both the individual and their family/caregiver(s) and highlight the role of the interprofessional team in evaluating and improving care for patients with these conditions.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 0.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of KLA and other lymphatic conditions, including current clinical trials. It will also share insights and perspectives from and provide strategies to support the well-being of both the individual and their family/caregiver(s).
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore the recent advances in the diagnosis and treatment of achondroplasia and other causes of disproportionate short stature. It will also share the importance of the interprofessional team to provide insights, perspectives and strategies to support the well-being of both the individual and their family/caregiver(s).

Pages